For complete information about the report, please visit our website
https://www.reportscorner.com/reports/26973/U.S-Orthopedic-Biomaterials-Market/
In 2012, the U.S. market for orthopedic biomaterials was valued at almost $3.4 billion. This total comprises eight different market segments.
The orthopedic biomaterials market has undergone a shift away from certain devices and towards new areas and medical devices. There is still tremendous potential for growth, especially in the younger market segments such as stem cells and concentration systems. Conversely, some products that previously experienced rapid market growth have now entered maturity, but even these markets are sustained by continued product evolution.
Scope: This report pertains to a forecast period of 10 years (2009 – 2019) for the U.S.
Report Contents:
Competitor Analysis
Identified Strategic Opportunities
Market Overview by Segment & Country
Trend Analysis by Segment & Country
Market Drivers & Limiters
Mergers & Acquisitions
Customer Feedback and Market Monitoring
Main Segments Included:
Orthopedic Bone Graft Substitute
Orthopedic Growth Factor
Orthopedic Stem Cell
Orthopedic Cell Therapy
Orthopedic Hyaluronic Acid Viscosupplementation
Orthopedic Tendon Graft
Orthopedic Cartilage Repair
Spinal Machined Bone Allograft
Sub-Segments Included:
Autograft
Standard Allograft
Demineralized Bone Matrix
Synthetic Bone Graft
Xenograft
BMP-2
BMP-7
Human Embryonic Stem Cells
Mesengchymal Stem Cells
Lumbar Spine Stem Cells
Cervical Spine Stem Cells
Platelet-Rich Plasma
Orthopedic Concentrated Bone Marrow Aspirate
Single-Injection
Three-Injection Cycle
Three/Five-Injection Cycle
BTB Graft
Soft Tissue Grafts
Ligament and Tendon Synthetic Graft
Osteochondral Allograft
Autologous Chondrocyte Implantation
Meniscal Allograft Tansplantation
ALIF Machined Bone Allograft
PLIF Machined Bone Allograft
TLIF Machined Bone Allograft
CIF Machined Bone Allograft
Companies Included:
Sanofi-Aventis/Genzyme
Bioventus
DePuy Synthes
Medtronic
Musculoskeletal Transplant Foundation
Stryker
RTI Biologics
NuVasive
Orthofix
LifeNet Health
AlloSource
Integra LifeSciences
Anika Therapeutics
Biomet
Ferring Pharmaceuticals
Exactech
Baxter
Harvest Technologies
Cytomedix
Wright Medical
Community Tissue Services
Olympus Biotech
Fidia
Arteriocyte
Alphatec Spine
Joint Restoration Foundation
University of Miami Tissue Bank
Celling Biosciences
Zimmer
Reasons To Buy:
This report analyzes and evaluates the current state of the market including existing and potential markets, product average selling prices, and unit volumes. The report also highlights the opportunities and potential hazards involved, and presents strategies for successfully navigating the market landscape. Furthermore, it seeks to identify the trends and technologies that will affect the future of each market segment and prepares an unbiased critical assessment of such market drivers and limiters based on our “ground up” approach, which includes primary and secondary research methods.
https://www.reportscorner.com/reports/26973/U.S-Orthopedic-Biomaterials-Market/
In 2012, the U.S. market for orthopedic biomaterials was valued at almost $3.4 billion. This total comprises eight different market segments.
The orthopedic biomaterials market has undergone a shift away from certain devices and towards new areas and medical devices. There is still tremendous potential for growth, especially in the younger market segments such as stem cells and concentration systems. Conversely, some products that previously experienced rapid market growth have now entered maturity, but even these markets are sustained by continued product evolution.
Scope: This report pertains to a forecast period of 10 years (2009 – 2019) for the U.S.
Report Contents:
Competitor Analysis
Identified Strategic Opportunities
Market Overview by Segment & Country
Trend Analysis by Segment & Country
Market Drivers & Limiters
Mergers & Acquisitions
Customer Feedback and Market Monitoring
Main Segments Included:
Orthopedic Bone Graft Substitute
Orthopedic Growth Factor
Orthopedic Stem Cell
Orthopedic Cell Therapy
Orthopedic Hyaluronic Acid Viscosupplementation
Orthopedic Tendon Graft
Orthopedic Cartilage Repair
Spinal Machined Bone Allograft
Sub-Segments Included:
Autograft
Standard Allograft
Demineralized Bone Matrix
Synthetic Bone Graft
Xenograft
BMP-2
BMP-7
Human Embryonic Stem Cells
Mesengchymal Stem Cells
Lumbar Spine Stem Cells
Cervical Spine Stem Cells
Platelet-Rich Plasma
Orthopedic Concentrated Bone Marrow Aspirate
Single-Injection
Three-Injection Cycle
Three/Five-Injection Cycle
BTB Graft
Soft Tissue Grafts
Ligament and Tendon Synthetic Graft
Osteochondral Allograft
Autologous Chondrocyte Implantation
Meniscal Allograft Tansplantation
ALIF Machined Bone Allograft
PLIF Machined Bone Allograft
TLIF Machined Bone Allograft
CIF Machined Bone Allograft
Companies Included:
Sanofi-Aventis/Genzyme
Bioventus
DePuy Synthes
Medtronic
Musculoskeletal Transplant Foundation
Stryker
RTI Biologics
NuVasive
Orthofix
LifeNet Health
AlloSource
Integra LifeSciences
Anika Therapeutics
Biomet
Ferring Pharmaceuticals
Exactech
Baxter
Harvest Technologies
Cytomedix
Wright Medical
Community Tissue Services
Olympus Biotech
Fidia
Arteriocyte
Alphatec Spine
Joint Restoration Foundation
University of Miami Tissue Bank
Celling Biosciences
Zimmer
Reasons To Buy:
This report analyzes and evaluates the current state of the market including existing and potential markets, product average selling prices, and unit volumes. The report also highlights the opportunities and potential hazards involved, and presents strategies for successfully navigating the market landscape. Furthermore, it seeks to identify the trends and technologies that will affect the future of each market segment and prepares an unbiased critical assessment of such market drivers and limiters based on our “ground up” approach, which includes primary and secondary research methods.
No comments:
Post a Comment